文献速递神经肿瘤

Olutasidenib(FT-2102)治疗复发或难治性IDH1突变胶质瘤:一项多中心、开放标签、Ib/II期试验

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
PubMed 文献 · Neuro Oncol · 2023-01-01

这项多中心、开放标签、非随机Ib/II期试验评估了Olutasidenib(FT-2102)在26例复发/难治性IDH1R132X突变胶质瘤患者中的安全性和临床活性;患者接受150 mg口服每日两次,未观察到剂量限制性毒性,疾病控制率为48%,2例(8%)达部分缓解,8例(32%)疾病稳定至少4个月,3-4级不良事件包括丙氨酸氨基转移酶升高和天冬氨酸氨基转移酶升高(各3例[12%])。

要点

  • Olutasidenib 150 mg口服每日两次在复发/难治性IDH1R132X突变胶质瘤中未观察到剂量限制性毒性。
  • 疾病控制率(客观缓解加疾病稳定)为48%,2例(8%)达部分缓解,8例(32%)疾病稳定至少4个月。
  • 3-4级不良事件(≥10%)包括丙氨酸氨基转移酶升高和天冬氨酸氨基转移酶升高,各3例(12%)。

核心结论

  • Olutasidenib 150 mg每日两次在复发/难治性IDH1R132X突变胶质瘤患者中耐受良好,并在这一经重度治疗人群中显示出初步的临床活性证据。

研究设计与样本

  • 这是一项开放标签、多中心、非随机Ib/II期临床试验。
  • 纳入年龄≥18岁、组织学确诊的IDH1R132X突变胶质瘤患者,这些患者在标准治疗后复发或进展,且有可测量病灶。
  • 患者接受Olutasidenib 150 mg口服每日两次,连续28天为一周期。
  • I期主要终点为剂量限制性毒性(第一周期)和安全性;II期主要终点为采用神经肿瘤学改良疗效评估标准评价的客观缓解率。
  • 共纳入26例患者,中位随访15.1个月(范围7.3‒19.4个月)。

主要发现

  • 单药胶质瘤队列中未观察到剂量限制性毒性,药代动力学关系支持Olutasidenib 150 mg每日两次作为推荐的II期剂量。
  • 在可评估缓解的人群中,疾病控制率(客观缓解加疾病稳定)为48%。
  • 2例(8%)患者最佳缓解为部分缓解,8例(32%)患者疾病稳定至少4个月。
  • 3-4级不良事件(≥10%)包括丙氨酸氨基转移酶升高和天冬氨酸氨基转移酶升高,各3例(12%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was to determine the safety and clinical activity of olutasidenib in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation. METHODS: This was an open-label, multicenter, nonrandomized, phase Ib/II clinical trial. Eligible patients (≥18 years) had histologically confirmed IDH1R132X-mutated glioma that relapsed or progressed on or following standard therapy and had measurable disease. Patients received olutasidenib, 150 mg orally twice daily (BID) in continuous 28-day cycles. The primary endpoints were dose-limiting toxicities (DLTs) (cycle 1) and safety in phase I and objective response rate using the Modified Response Assessment in Neuro-Oncology criteria in phase II. RESULTS: Twenty-six patients were enrolled and followed for a median 15.1 months (7.3‒19.4). No DLTs were observed in the single-agent glioma cohort and the pharmacokinetic relationship supported olutasidenib 150 mg BID as the recommended phase II dose. In the response-evaluable population, disease control rate (objective response plus stable disease) was 48%. Two (8%) patients demonstrated a best response of partial response and eight (32%) had stable disease for at least 4 months. Grade 3‒4 adverse events (≥10%) included alanine aminotransferase increased and aspartate aminotransferase increased (three [12%], each). CONCLUSIONS: Olutasidenib 150 mg BID was well tolerated in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation and demonstrated preliminary evidence of clinical activity in this heavily pretreated population.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. de la Fuente MI, Colman H, Rosenthal M, et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro Oncol. 2023. PMID: 35639513. doi:10.1093/neuonc/noac139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。